Status:
UNKNOWN
Arteriovenous Fistula Maturation in Hemodialysis Patients With or Without Positive Antiphospholipid Antibodies
Lead Sponsor:
Brugmann University Hospital
Conditions:
Chronic Kidney Diseases
Eligibility:
All Genders
18-75 years
Brief Summary
Hemodialysis (HD) is one of the most often used modalities of blood epuration in ends-stage renal diseases (ESRD) and requires the creation of a patent vascular access such as an arteriovenous fistula...
Eligibility Criteria
Inclusion
- Incident patients with chronic kidney disease (CKD) on stage G3b to G5, not end-stage renal disease, according to KDIGO guidelines
Exclusion
- Patient already on hemodialysis maintenance therapy, or switching from peritoneal dialysis to hemodialysis
- Arteriovenous fistula creation not feasible surgically or technically, or surgery contra-indicated
- Known thrombophilia other than antiphospholipid syndrome
- Active neoplasia
- aPL assays not relevant (treatment, inflammatory state, etc...)
Key Trial Info
Start Date :
July 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06112821
Start Date
July 1 2022
End Date
June 30 2024
Last Update
November 2 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brugmann University Hospital
Brussels, Belgium, 1020